> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Estuary Raises $103M to Reverse Polycystic Kidney Disease With Local Gene Therapy - URL: https://nexi.fund/estuary-adpkd-gene-therapy-2026/ - Published: 2026-10-17T13:30:36.000Z - Updated: 2026-10-17T13:30:36.000Z - Description: A Yale spinout launched with $103 million to test whether gene therapy delivered locally into the kidney can do what the one approved drug cannot: stop, and possibly reverse, polycystic kidney disease. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-7, #hook-number, #track-E, #layout-interview-voice $103 million to treat one organ. Estuary Biotherapeutics raised that to go after a disease with a single approved drug, no cure, and a delivery problem that has defeated every gene therapy pointed at it so far. Sackett found the science where biotech founders often find it: by accident, while reading. In 2021 he came across a paper in *Nature Genetics* from Stefan Somlo's lab at Yale School of Medicine. Reactivate the polycystin proteins the disease switches off, the paper showed in mice, and cysts that already exist shrink back. Not prevented. Reversed. He wrote to the lab. By 2022, Estuary existed around that result, with Somlo and Michael Caplan, also at Yale, as scientific co-founders and Xavier Anguela, a vice president of gene therapy at Eli Lilly, as the fourth. On October 16, 2026, the company came out of stealth with $93 million in Series A money led by RA Capital Management, a $10 million seed co-led by 4BIO Capital and GV, and $103 million committed in total. ## A disease with eight million patients and one pill ADPKD is among the most common inherited diseases on earth. Roughly one in 400 to 1,000 people carry it, more than 8 million globally, and about 90% of them have a mutation in one of two genes: PKD1 or PKD2\. Cysts form in both kidneys and grow for decades, displacing working tissue until the organ fails. For patients whose disease progresses quickly, end-stage kidney failure lands between the ages of 45 and 65\. In the United States, the direct cost of that care runs above $7 billion a year. ## Why the bet is delivery, not biology Gene therapy has no shortage of failed attempts on the kidney. The obstacle is rarely the target; it is reaching the right cells in an organ whose entire job is to filter blood. Systemic AAV doses large enough to reach the nephron have produced the safety signals that have slowed the whole field. Estuary's claim is narrower, and therefore easier to test. It delivers the vector locally, into the kidney, aimed at kidney epithelial cells, to restore protein across the entire nephron. CEO Wayne Sackett frames the company around that single engineering problem. > The challenge ahead is largely one of engineering and execution: effectively delivering genetic medicines to the relevant cells in the kidney and translating that science into meaningful outcomes for patients.— Wayne Sackett, co-founder and CEO, Estuary Biotherapeutics Sackett is not the first founder to say delivery is everything. He is, though, working on a target where the biology has already been shown to reverse disease in animals at two separate stages — one that maps to mid-stage disease, one more advanced. That is the part investors actually paid for. ## The protein small enough for a virus The second half of the pitch is a packaging trick. Full-length PKD1 is too large to fit inside an AAV vector. Caplan's lab found that only a small functional region of the polycystin-1 protein is needed to suppress the disease. EST-101 carries that trimmed sequence inside the same AAV that delivers EST-201, the company's full-length PKD2 program. Two programs, one vector, one route of administration. EST-201 targets patients with a PKD2 mutation and is expected to reach the clinic in 2027\. EST-101 covers PKD1, the mutation behind the large majority of cases, and is expected to follow in 2028\. A third program, EST-102, waits behind both. Estuary's internal word for it is compounding: each later program inherits the delivery work paid for by the first. The company also argues the same route can reach beyond inherited disease, toward the far larger pool of common kidney conditions that share the kidney's basic biology but not its fame. > We are developing our programs as potentially one-time, locally delivered AAV gene therapies with the goal of achieving long-term, durable gene expression. If successful, we believe this approach could move treatment beyond slowing disease progression toward potentially halting or reversing it.— Wayne Sackett, on Estuary's approach ## The field they still have to beat The competition is real and already funded. Otsuka's tolvaptan, an arginine vasopressin V2-receptor antagonist, remains the only FDA-approved drug in ADPKD; it lowers the elevated cyclic AMP that drives cyst growth, and it works by degrees. Novartis paid $800 million upfront for Regulus Therapeutics to acquire farabursen, an RNA-targeting oligonucleotide now in Phase 1\. SonoThera raised $125 million in June 2026 for a pipeline that includes a kidney gene therapy. The wider cell-and-gene therapy market is moving with it: as we wrote in October, New Zealand's [BioOra raised NZ$30 million and signed a CAR T licence](https://nexi.fund/bioora-series-a2-car-t-licence-2026/) ahead of a planned 2028 listing. Estuary sits earlier than all three. Both lead programs are preclinical. The new money buys clinical proof of concept, not a product, and the risk profile of gene therapy for a chronic disease is unforgiving — a one-time treatment that fails has no second dose to fall back on. > Estuary's programs have the potential to transform the care of patients with ADPKD. The differentiated approach pairs a known gene therapy modality with focal, kidney-directed delivery designed to reach the nephron directly.— Emily Minkow, managing director, RA Capital Management The advisory bench suggests the founders know what they are walking into. Frank Czerwiec, who led the clinical development of tolvaptan, is an adviser. So is Jeff Marrazzo, co-founder and former CEO of Spark Therapeutics, which Roche bought for almost $5 billion in 2019\. Between them, they have lived through a kidney drug's regulatory path and a gene therapy's commercial one. ## What would make any of this real The near-term signal is the one gene-therapy investors always watch: a first human dose that shows expression in the target organ without the systemic toxicity that has doomed larger doses elsewhere. EST-201's 2027 entry is the line to mark. If local delivery holds, the platform argument — one route, many kidney diseases — becomes the second bet. Over the whole field sits one number. Tolvaptan's best outcome is a slower decline. Estuary is selling $103 million of investor confidence on the claim that decline can be stopped, and possibly turned around. Mice have shown it can be done. People have not. [ Biogen-backed Estuary raises $93M for a kidney-disease gene therapy The most detailed account of the founding science, the former Biogen leadership team, and the two lead programs that anchor the round. BioPharma Dive ](https://www.biopharmadive.com/news/estuary-kidney-disease-gene-therapy-launch-emerged-biogen-biotech-startup/833114/?ref=nexi.fund) The clearest read on how the Yale research became a company, and what the Series A is actually paying for. [ Estuary flows out of stealth with $103M for kidney gene therapies Program-level detail on EST-201 and EST-101, the local AAV delivery approach, and the incumbents already in the ADPKD space. Fierce Biotech ](https://www.fiercebiotech.com/biotech/estuary-emerges-stealth-103m-its-gene-therapies-kidney-disease?ref=nexi.fund) Useful for pinning down the mechanism — and the fact that tolvaptan remains the only approved drug in the category. [ Estuary Biotherapeutics launches with $103 million for targeted kidney gene therapies The primary announcement, including the financing structure, investor list, and the company's own framing of the delivery problem. Estuary Biotherapeutics ](https://estuarybio.com/news/estuary-series-a?ref=nexi.fund) Primary source for the round and the pipeline claims, quoted here directly rather than secondhand.